CliffBio
small molecule

EPINEPHRINE

EPINEPHRINE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameEPINEPHRINE
Active ingredientEPINEPHRINE
Strength1MG/ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.